Back to News
Market Impact: 0.18
Lexicon Pharmaceuticals Consensus Price Target Increased by 17.91% to $4.64
Source: Nasdaq
Analyst EstimatesAnalyst InsightsHealthcare & Biotech
The aggregate one-year analyst price target for Lexicon Pharmaceuticals was raised 17.91% to $4.64 per share from $3.93 as of September 11, 2026. The revision indicates improved analyst expectations for the biotech company, though the article provides no underlying earnings, clinical, or operational catalyst.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.28
Ticker Sentiment
LXRX0.35
More News
- Your health insurance premiums may take a big jump in 2027 — here's why
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
- Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
- Tesla reports 486,532 vehicle deliveries for third quarter, topping expectation
- Why AMD Stock Jumped 30% in September
- Nike falls to 13-year low. Why analysts don't think the selling is over yet
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Alternative Data Due Diligence for Institutional Investors
- Introducing AllMind: A New Data & AI Workspace for Institutional Investors